ARX788 for HER2-positive breast cancer after T-DXd treatment
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug called ARX788 for people with HER2-positive breast cancer that has spread and who have already been treated with T-DXd (trastuzumab deruxtecan). It aims to see if ARX788 can help when other treatments stop working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your breast cancer is HER2-positive (a specific protein test shows high levels).
- Your cancer has spread to nearby tissues or other parts of the body and cannot be removed with surgery.
- You have already received T-DXd (a type of targeted therapy) for advanced breast cancer.
- Your organs (bone marrow, liver, kidneys) and blood clotting work well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how well an imaging test can predict the effectiveness of the drug T-DXd in people with HER2-positive breast cancer that has spread to the brain. It aims to see if a special scan can help guide treatment.
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
This trial tests a new combination of a targeted drug (T-DXd) with brain radiation for women with breast cancer that has spread to the brain and is HER2-positive or HER2-low. The goal is to see if this approach is safe and works better than radiation alone.
This study is testing a new drug called trastuzumab deruxtecan (also known as T-DXd) in women with advanced breast cancer that is hormone receptor positive and has a very low level of HER2 (called HER2-ultralow). The trial aims to see if this drug can help shrink or slow the growth of the cancer in this specific group of patients.
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
This trial tests a combination of two targeted therapies, Trastuzumab Deruxtecan (T-DXd) and Pyrotinib, as a first treatment for HER2-positive breast cancer that has spread or cannot be removed. It aims to see if this combination works better than standard treatments.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.